Palisade Asset Management LLC maintained its stake in C.R. Bard, Inc. (NYSE:BCR) during the second quarter, Holdings Channel reports. The firm owned 5,115 shares of the medical instruments supplier’s stock at the end of the second quarter. Palisade Asset Management LLC’s holdings in C.R. Bard were worth $1,617,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the company. Cribstone Capital Management LLC acquired a new stake in C.R. Bard during the first quarter valued at approximately $130,000. Whittier Trust Co. raised its stake in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in C.R. Bard during the first quarter valued at approximately $148,000. SRS Capital Advisors Inc. raised its stake in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after buying an additional 369 shares during the last quarter. 85.32% of the stock is currently owned by institutional investors and hedge funds.

C.R. Bard, Inc. (BCR) opened at 318.63 on Thursday. The company has a market cap of $23.16 billion, a P/E ratio of 41.83 and a beta of 0.59. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The company’s 50-day moving average is $318.77 and its 200-day moving average is $282.55.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same period in the previous year, the business posted $2.54 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts expect that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were paid a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s payout ratio is 13.67%.

WARNING: This article was reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/10/c-r-bard-inc-nysebcr-position-held-by-palisade-asset-management-llc.html.

Several research firms recently commented on BCR. Cowen and Company boosted their price objective on shares of C.R. Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research note on Monday, April 24th. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price on the stock in a research note on Tuesday, June 6th. Jefferies Group LLC upped their target price on shares of C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a research note on Monday, April 24th. Finally, Wells Fargo & Company downgraded shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. One analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $285.67.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.